LKB1-AMPK activators for therapeutic use in polycystic kidney disease

US10450305B2 · kind B2 · utility

Assignee

• University of Kansas · US

Inventors

• Darren Paul Wallace · Baldwin City, US
• Bhaskar C. Das · West Nyack, US

Key dates

• Filing date: Dec 7, 2018
• Grant date: Oct 22, 2019
• Expiry date: Dec 7, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F5/025
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds can be used for treating polycystic kidney disease (PKD). As such, these compounds can be used in associated methods. The methods can include: method of modulating (e.g., activating) Liver kinase B1 (LKB1); method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway. The disease modulated by mTOR is selected from the group consisting of multiple types of cancer, including breast cancer, renal cell carcinoma, colorectal cancer, prostate cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, skin cancer, glioblastoma, bone metastatic cancer, head and neck cancer, and leukemia, kidney disease, obesity, neuro disorders and alcohol-related chronic diseases.